Last reviewed 2026-04-22 · How we verify

Carbamazepine-Implant

Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity.

Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity. Used for Epilepsy / seizure disorders, Trigeminal neuralgia, Bipolar disorder.

At a glance

Mechanism of action

Carbamazepine works primarily by inhibiting voltage-gated sodium channels, which decreases the influx of sodium ions into neurons and stabilizes the neuronal membrane. This reduces the frequency of action potentials and prevents the spread of abnormal electrical activity characteristic of seizures. The implant formulation provides sustained local or systemic drug delivery to maintain therapeutic levels.

Approved indications

• Epilepsy / seizure disorders
• Trigeminal neuralgia
• Bipolar disorder

Common side effects

• Dizziness
• Ataxia
• Diplopia
• Nausea
• Rash / Stevens-Johnson syndrome
• Hyponatremia
• Agranulocytosis

Key clinical trials

• Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
• Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Carbamazepine-Implant CI brief — competitive landscape report
• Carbamazepine-Implant updates RSS · CI watch RSS
• University of Sao Paulo portfolio CI